Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15230892 | 0.91 | PIM1 (0.49) | PIM1PIM2 | |
| SCHEMBL15231524 | 0.91 | PIM1 (0.49) | PIM1PIM2 | |
| SCHEMBL17268422 | 0.86 | PIM1 (0.54) | PIM1PIM2 | |
| SCHEMBL15231180 | 0.85 | PIM1 (0.51) | PIM1PIM2 | |
| SCHEMBL15231000 | 0.84 | PIM1 (0.59) | PIM1PIM2 | |
| SCHEMBL15231821 | 0.81 | PIM1 (0.54) | PIM1PIM2 | |
| SCHEMBL15231051 | 0.80 | PIM1 (0.53) | PIM1PIM2 | |
| SCHEMBL15230778 | 0.79 | PIM1 (0.52) | PIM1PIM2 | |
| SCHEMBL15243875 | 0.79 | PIM1 (0.44) | PIM1PIM2 | |
| SCHEMBL15231470 | 0.78 | PIM1 (0.58) | PIM1PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9394297-B2 | Amides as pim inhibitors | AMGEN INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-20150329538-A1 | AMIDES AS PIM INHIBITORS | AMGEN INC. (US) | 2015-11-19 | — | — | US | disclosed |
| WO-2013130660-A1 | AMIDES AS PIM INHIBITORS | AMGEN INC. (US) | 2013-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329538-A1 | AMIDES AS PIM INHIBITORS | PIM1, PIM3, PIM2 | PIM1 1/4885PIM2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.